Navigation Links
Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
Date:3/24/2011

BEDMINSTER, N.J., March 24, 2011 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Jerry Wisler, President and Chief Executive Officer, will present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference at the Grand Hyatt in New York, on March 31, 2011 at 2:30pm ET.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.  The Company recently initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (greater than or equal to 500 mg/dL). Future planned clinical trials for Epanova include patients with high triglycerides (greater than or equal to 200 mg/dL and less than or equal to 500 mg/dL) currently on statin therapy.  Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss Company that is the owner of the product.
For more information, please visit www.omthera.com.Omthera Contacts:Omthera Media Relations:Douglas Carr

Eric GoldmanFinancial Controller

Rx Communications GroupOmthera Pharmaceuticals

917-322-2563908-741-4323

egoldman@rxir.comDCarr@Omthera.com
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
2. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014   LabStyle Innovations Corp . (OTCQB: ... today announced that it has closed a $4.2 ... preferred stock and warrants.  No placement agent was ... LabStyle expects to secure net proceeds of approximately ... LabStyle intends to use the net proceeds from ...
(Date:9/23/2014)... MINNETONKA, Minn. , Sept. 23, 2014   MedNet ... clinical study management systems, is pleased to announce that it ... for Clinical Data Management (SCDM) Annual Conference, to be held ... Las Vegas , Nevada. MedNet team members, in conjunction ... Partner Organizations who will also be in attendance, will ...
(Date:9/23/2014)... ORLANDO, Fla. and DUBLIN ... Inc. (OTC-BB: TNIB) ("we" or the "Company"), a ... innovative therapies for autoimmune diseases in emerging nations, ... has approved our common stock for DTC,s Deposit ... Fast Automated Securities Transfer Service ("FAST") transfer agent ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5MedNet Solutions - Proud To Sponsor The SCDM 2014 Annual Conference 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... Reports on 11 Patients at SAWCPRINCETON, N.J., April 29 ... (OTC Bulletin Board: DSCI), a provider of advanced ... on the Advances in Wound Care (SAWC) in Dallas, Jason ... South Florida, revealed details of a recently concluded 11-patient venous ...
... the REDUCE trial results at the American Urological Association annual ... as dutasteride (Avodart), a drug used to treat benign prostatic ... of prostate cancer in men with an increased risk of ... an additional tool in the fight against prostate cancer. ...
Cached Medicine Technology:Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R) 2Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R) 3Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2
(Date:9/23/2014)... York, NY (PRWEB) September 23, 2014 ... a moderate rate over the past five years. Growth ... health consciousness has encouraged Canadians to consume more fish ... has encouraged food retailers and food-service establishments to increase ... increasing industry revenue. Additionally, strong economic growth in much ...
(Date:9/23/2014)... 2014 Oaksterdam University has begun publishing ... its first post, the University addresses the need for ... industry. , The cannabis industry is becoming big business. ... an 18-month boost of more than $600 million in ... sales. And, the new legal recreational marijuana market in ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT ... from Sacramento, Ca.. "Call lights are often found on the ... the IV pole out of the patient's reach. In order ... whenever they need it, I created this caddy." , She ... call device within easy reach. The accessory ensures that the ...
(Date:9/23/2014)... California, Davis, and Academia Sinica, the preeminent academic ... entered into a collaborative agreement to develop a ... cutting-edge research with opportunities to translate innovative technologies ... The agreement was signed Sept.12 in Taipei by ... Davis and President Chi-Huey Wong of Academia Sinica. ...
(Date:9/23/2014)... September 23, 2014 AttorneyOne.com, a recognized ... the latest information from the FDA on Jalapeno ... that its Private Label Jalapeno Bagels are recalled as ... Publix Jalapeno Bagels were sold in the ... , Taking into consideration the latest developments, AttorneyOne.com ...
Breaking Medicine News(10 mins):Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: ... published by the Seattle Times reporting ... incorrectly reported that CellCyte ,closes.,In CellCyte,s August 14, ... its bioreactor business segment and generally described its ...
... Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today announced that its subsidiary, Watson Laboratories, ... Food and Drug Administration on its,Abbreviated New Drug ... USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl,estradiol ...
... Priority ReviewEAST BRUNSWICK, N.J., Dec. 29 Savient ... announced that the U.S. Food and Drug Administration ... License Application (BLA) for pegloticase, a novel biological ... also granted the Company,s BLA with a priority ...
... Cross and Blue Shield of Oklahoma announced today the ... their next policy year. This change will not in ... always been available to children with autism. Blue Cross ... interests in the benefits and coverage of certain autism-related ...
... Dec. 29 Eastern Life & Health Insurance Company (ELH), ... EIHI ), announced today that it will add vision to ... include a vision insurance plan and a vision discount program, ... "Adding vision to ELH,s product portfolio enables employers to offer ...
... 29 Life for Relief and Development (LIFE), a ... the civilian victims of the recent conflict in Gaza. ... non-governmental organizations operating in the area, LIFE has obtained ... relief items to Gaza via a specially designated humanitarian ...
Cached Medicine News:Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 2Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 3Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 4Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 5Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 3Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 4Health News:Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits 2Health News:Eastern Life & Health Introduces New Vision Product 2Health News:Eastern Life & Health Introduces New Vision Product 3
... workmanship are the hallmark of these stereozoom ... mind. The top (incident) circular 9W fluorescent ... while remaining cool to the touch. Binocular ... 10x to 44x zoom magnification or high-power ...
... system expandability: the first inverted microscope to ... infinity space. Multi-port design enables optical input/output ... variety of illumination and detector equipment. Extendable ... an optional light source and other attachments ...
... Megapixel color imaging camera system designed ... high performance, megapixel digital cameras provides ... view them on a PC via ... This "live" previewing capability is accompanied ...
... camera with direct digital output. Three-chip color ... Olympus wide array of high-quality color video ... and flexibility you need for an efficient ... high-resolution, real-time image of your specimen that ...
Medicine Products: